

Raffaella Lionetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8534819/publications.pdf>

Version: 2024-02-01

8
papers

252
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

527
citing authors

#	ARTICLE	IF	CITATIONS
1	Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients. <i>Liver International</i> , 2022, 42, 180-186.	3.9	36
2	SarcoModel: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation. <i>Liver International</i> , 2021, 41, 1629-1640.	3.9	17
3	Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. <i>Annals of Hepatology</i> , 2019, 18, 434-438.	1.5	8
4	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , 2018, 32, e13165.	1.6	10
5	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	1.6	3
6	Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. <i>Viruses</i> , 2017, 9, 212.	3.3	10
7	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	2.4	73
8	Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. <i>Digestive and Liver Disease</i> , 2014, 46, 923-927.	0.9	95